MMJ for Hepatic Enchephalopathy

Photo Credit: Medical Marijuana Inc. 

Photo Credit: Medical Marijuana Inc. 

Hepatic encephalopathy (HE) results from the liver's inability to filter toxins out of the blood, which can reduce brain function. When the liver is unable to process toxins out of the blood, it can lead to a buildup of these toxins which can create oxidative stress and end up damaging the nervous system. There are a wide range of symptoms associated with HE, including sweet-odor breath, changes in sleep cycles, changes in thought, confusion or disorientation, forgetfulness, mood changes, poor judgment, a lack of concentration, shaky arms and hands, agitation or excitement, drowsiness, sluggish movements, slurred speech, and the possibility of entering a coma. In some cases, HE can be treated in corrected, but in others may worsen over time, and both types could lead to an irreversible coma or even death.

Cannabis may be able to assist in the prevention and treatment of hepatic encephalopathy, and one pharmaceutical company, Kannalife, is already jumping on board developing cannabinoid-based medications for the treatment of HE as well as chronic traumatic encephalopathy. Kannalife currently holds a license with the National Institute of Health for the Commercialization of U.S. Patent titled "cannabinoids as antioxidants and neuroprotectants." Research has shown CBD is effective at reducing oxidative stress, and it can also aide recovery from oxidative stress-related conditions like HE and CTE because of its anti-inflammatory and neuroprotective properties.

This information has been brought to you by Medical Marijuana Inc. and approved by our Chief Medical Officer.